Clobetasol

DB11750ApprovedInvestigationalWithdrawnSmall moleculeCorticosteroids

Clobetasol is under investigation for the treatment of Scleroderma. Clobetasol has been investigated for the prevention of Psoriasis and Cutaneous Atrophy Due to Corticosteroids.

Formula / weight: C₂₂H₂₈ClFO₄ · 410.907 g/mol (avg)

Resolves to

Compound

UNIIADN79D536HCAS25122-41-2ChEMBLCHEMBL1201362ChEBI205919PubChem5311051

Clinical / RWD

RxNorm2590ATCD07AD01ATCD07CD01

Structure

InChIKeyFCSHDIVRCWTZOX-DVTGEIKXSA-NSMILES[H][C@@]12C[C@H](C)[C@](O)(C(=O)CCl)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C

Targets

P04054PLA2G1B

What you can answer from here — as of March 06, 2025

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

176Drug interactionsStructured to mechanism, not free text

24Clinical trialsPhase, status and sponsor resolved per trial

4Marketed productsAcross 3 countries and 2 labellers

2ATC codesIncluding every combination product, plus 25 drug categories

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Clobetasol, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account